Search | Clinical Trials Finder

Conditions: Short Bowel Syndrome
Interventions: Pancreatic Enzyme; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 10
States / cities: Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more

Conditions: Exocrine Pancreatic Insufficiency
Interventions: VIOKASE 16; Drug
Lead sponsor: Axcan Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Gainesville, Florida • Mayo Clinic- Rochester, Minnesota

Conditions: Cystic Fibrosis
Interventions: Pancrelipase; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 13
States / cities: Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more

Conditions: Dyspepsia
Interventions: Zypan, Placebo Comparator; Dietary Supplement
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions: NHS7108, Zenpep®; Drug
Lead sponsor: Aimmune Nestlé Health Science US R&D, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Los Angeles, California • Orlando, Florida + 5 more

Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: ANG003 Dose A, ANG003 Dose B, Creon; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more

Conditions: Postprandial Bloating, Postprandial Belching, Postprandial Eructation
Interventions: Pancrelipase (Creon) 2 tablets with each meal; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cystic Fibrosis
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more

Conditions: Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Stanford, California • Gainesville, Florida • Baltimore, Maryland + 3 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: Ultrase® MT20, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Grand Rapids, Michigan • Cleveland, Ohio • Hershey, Pennsylvania + 1 more

Conditions: Cystic Fibrosis
Interventions: Ethambutol, Rifampin, Azithromycin, Pancrelipase; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis, Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more

Conditions: Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase delayed release capsule, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 23
States / cities: Scottsdale, Arizona • Bristol, Connecticut • Tampa, Florida + 20 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: PANCRECARB® (pancrelipase), Placebo; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: Up to 7 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more

Conditions: Type 1 Diabetes
Interventions: CREON, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Celiac Disease
Interventions: pancrelipase; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Ultrase® MT12; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 15
States / cities: Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more

Conditions: Pancreatic Cancer
Interventions: CABOZANTINIB, gemcitabine; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Cystic Fibrosis
Interventions: Pancrelipase; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Ultrase® MT20; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania

Search by objective public record fields.

Use of Pancreatic Enzymes in Short Bowel Syndrome

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Zypan Functional Dyspepsia

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Efficacy of Pancrelipase on Postprandial Belching and Bloating.

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes

Pancreatic Enzyme Supplementation for Celiac Disease

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)